OpenNashEarnings

Health Care · NYSE: COR

Cencora earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends September · next results expected around 3 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q4 FY2026

Cencora is reorganizing into two customer-focused segments and buying American Oncology Network, deepening its bet on specialty and oncology physician practices after closing OneOncology.

Cencora closed its OneOncology acquisition in February 2026, adding a physician-practice platform that lifted U.S. profitability. Specialty product sales to health systems and physician practices grew, as did GLP-1 sales, which carry lower margins. Brand manufacturer price declines and lower sales to its large mail order customer partly offset growth. It also sold U.S. Consulting Services in April 2026.

Read the Q4 FY2026 summary →Q4 FY2026 slides (PDF) ↗

Quarters

KPI history

Revenue$84.8B+5.1% y/yQ3 FY26
Q4 FY24: $79.1B (worked out from the annual figure)Q4 24$79.1BQ1 FY25: $81.5BQ1 25$81.5BQ2 FY25: $75.5BQ2 25$75.5BQ3 FY25: $80.7BQ3 25$80.7BQ4 FY25: $83.7B (worked out from the annual figure)Q4 25$83.7BQ1 FY26: $85.9BQ1 26$85.9BQ2 FY26: $78.4BQ2 26$78.4BQ3 FY26: $84.8BQ3 26$84.8B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$79.1B *
Q1 FY25$81.5B
Q2 FY25$75.5B
Q3 FY25$80.7B
Q4 FY25$83.7B *
Q1 FY26$85.9B
Q2 FY26$78.4B
Q3 FY26$84.8B
Diluted EPS (GAAP)$3.94+11.9% y/yQ3 FY26
Q1 FY25: $2.50Q1 25$2.50Q2 FY25: $3.68Q2 25$3.68Q3 FY25: $3.52Q3 25$3.52Q1 FY26: $2.87Q1 26$2.87Q2 FY26: $8.40Q2 26$8.40Q3 FY26: $3.94Q3 26$3.94
Data
Q1 FY25$2.50
Q2 FY25$3.68
Q3 FY25$3.52
Q1 FY26$2.87
Q2 FY26$8.40
Q3 FY26$3.94

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin1.3%+0.2 pts y/yQ3 FY26
Q4 FY24: 0.2%Q4 240.2%Q1 FY25: 0.9%Q1 250.9%Q2 FY25: 1.4%Q2 251.4%Q3 FY25: 1.1%Q3 251.1%Q4 FY25: 0.0%Q4 250.0%Q1 FY26: 0.9%Q1 260.9%Q2 FY26: 1.5%Q2 261.5%Q3 FY26: 1.3%Q3 261.3%
Data
Q4 FY240.2%
Q1 FY250.9%
Q2 FY251.4%
Q3 FY251.1%
Q4 FY250.0%
Q1 FY260.9%
Q2 FY261.5%
Q3 FY261.3%
Free cash flow$2.4BQ3 FY26
Q4 FY24: $818.1MQ4 24$818.1MQ1 FY25: -$2.8BQ1 25-$2.8BQ2 FY25: $3.2BQ2 25$3.2BQ3 FY25: -$74.0MQ3 25-$74.0MQ4 FY25: $2.9BQ4 25$2.9BQ1 FY26: -$2.4BQ1 26-$2.4BQ2 FY26: $1.2BQ2 26$1.2BQ3 FY26: $2.4BQ3 26$2.4B
Data
Q4 FY24$818.1M
Q1 FY25-$2.8B
Q2 FY25$3.2B
Q3 FY25-$74.0M
Q4 FY25$2.9B
Q1 FY26-$2.4B
Q2 FY26$1.2B
Q3 FY26$2.4B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$79.1Bd$81.5B$75.5B$80.7B$83.7Bd$85.9B$78.4B$84.8B
Gross margin3.2%3.1%4.1%3.6%3.5%3.6%4.6%4.3%
Operating income$126.6Md$706.3M$1.0B$867.7M$18.5Md$760.4M$1.1B$1.1B
Operating margin0.2%0.9%1.4%1.1%0.0%0.9%1.5%1.3%
Net income$3.4Md$488.6M$717.9M$687.4M-$339.7Md$559.6M$1.6B$763.5M
Diluted EPS—$2.50$3.68$3.52—$2.87$8.40$3.94
Operating cash flow$1.0Bd-$2.7B$3.4Bd$109.2Md$3.1Bd-$2.3B$1.3Bd$2.7Bd
Capital expenditure$182.3Md$105.9M$129.1Md$183.2Md$249.8Md$119.4M$165.6Md$226.0Md
Free cash flow$818.1M-$2.8B$3.2B-$74.0M$2.9B-$2.4B$1.2B$2.4B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings